Injections of Botulinum Toxin A into the detrusor to treat neurogenic detrusor overactivity secondary to spinal cord injury

International Urology and Nephrology

Volumn 43, Issue 3, 2011, Pages 655-662

  Chen, Guoqing ^a   Liao, Limin ^a  

^a CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

Botulinum toxin A; Neurogenic detrusor overactivity; Spinal cord injuries; Urinary incontinence

Indexed keywords

BOTULINUM TOXIN A; TOLTERODINE;

ADOLESCENT; ADULT; AGED; ARTICLE; CONTROLLED STUDY; CYSTOMETRY; CYSTOSCOPY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; INTERMITTENT CATHETERIZATION; MAJOR CLINICAL STUDY; MALE; MICTURITION; NEUROGENIC BLADDER; OVERACTIVE BLADDER; PATIENT SATISFACTION; REFLEX; SPINAL CORD INJURY; TREATMENT DURATION; TREATMENT RESPONSE; URINARY FREQUENCY; URINE INCONTINENCE; URINE VOLUME; URODYNAMICS;

ADOLESCENT; ADULT; AGED; BOTULINUM TOXINS, TYPE A; FEMALE; HUMANS; MALE; MIDDLE AGED; MUSCLE, SMOOTH; NEUROMUSCULAR AGENTS; QUALITY OF LIFE; RETROSPECTIVE STUDIES; SPINAL CORD INJURIES; URINARY BLADDER; URINARY BLADDER, NEUROGENIC; URINARY BLADDER, OVERACTIVE; URINARY INCONTINENCE; URODYNAMICS; YOUNG ADULT;

EID: 80555127379     PISSN: 03011623     EISSN: 15732584     Source Type: Journal    
DOI: 10.1007/s11255-010-9873-x     Document Type: Article

References (25)

1. Sekhon LH, Fehlings MG (2001) Epidemiology,demographics, and pathophysiology of acute spinal cord injury. Spine 26(24 Suppl):S2-S12 (Pubitemid 34019773)
2. Riccabona M, Koen M, Schindler M et al (2004) Botulinum-A toxin injection into the detrusor: A safe alternative in the treatment of children with myelomeningocele with detrusor hyperreflexia. J Urol 171:845-848 (Pubitemid 38090518)
3. Schurch B, Stohrer M, Kramer G et al (2000) Botulinum-A toxin for treating detrusor hyperreflexia in spinal cord injured patients: A new alternative to anticholinergic drugs? Preliminary results. J Urol 164:692-697 (Pubitemid 30637604)
4. Lacy DB, Tepp W, Cohen AC et al (1998) Crystal structure of botulinum neurotoxin type A and implications for toxicity. Nat Struct Biol 5:898-902 (Pubitemid 28467413)
5. de Paiva A, Meunier FA, Molgo J et al (1999) Functional repair of motor endplates after botulinum neurotoxin type A poisoning: Biphasic switch of synaptic activity between nerve sprouts and their parent terminals. Proc Natl Acad Sci USA 96:3200-3205 (Pubitemid 29148868)
6. Stohrer M, Schurch B, Kramer G et al (1999) Botulinum A toxin in the treatment of detrusor hyperreflexia in spinal cord injury. A new alternative to medical and surgical procedures? Neurourol Urodyn 18:401-402
7. Rieder CR, Schestatsky P, Socal MP et al (2007) A doubleblind, randomized, crossover study of prosigne versus botox in patients with blepharospasm and hemifacial spasm. Clin Neuropharmacol 30:39-42 (Pubitemid 46204316)
8. Quagliato EM, Carelli EF, Viana MA (2010) Prospective, randomized, double-blind study, comparing botulinum toxins type A botox and prosigne for blepharospasm and hemifacial spasm treatment. Clin Neuropharmacol 33: 27-31
9. Maynard FM Jr, Bracken MB, Creasey G et al (1997) International standards for neurological and functional classification of spinal cord injury. American spinal injury association. Spinal Cord 35:266-274 (Pubitemid 27235039)
10. Blaivas JG, Awad SA, Bissada N et al (2005) Urodynamic procedures: Recommendations of the urodynamic society I. Procedures that should be available for routine urologic practice. Neurourol Urodyn 1:51-55
11. Schurch B, Denys P, Kozma CM et al (2007) Botulinum toxin A improves the quality of life of patients with neurogenic urinary incontinence. Eur Urol 52:850-858
12. Schulte-Baukloh H, Weiss C, Stolze T et al (2005) Botulinum-A toxin detrusor and sphincter injection in treatment of overactive bladder syndrome: Objective outcome and patient satisfaction. Eur Urol 48:984-990 (Pubitemid 41641650)
13. Reitz A, Stohrer M, Kramer G et al (2004) European experience of 200 cases treated with botulinum-A toxin injections into the detrusor muscle for urinary incontinence due to neurogenic detrusor overactivity. Eur Urol 45:510-515 (Pubitemid 38376219)
14. Smith CP, Gangitano DA, Munoz A et al (2008) Botulinum toxin type A normalizes alterations in urothelial ATP and NO release induced by chronic spinal cord injury. Neurochem Int 52:1068-1075
15. Dixon J, Glosing J (1987) Structure and innervation in the human. In: Torrens M, Morrison JFB (eds) The physiology of the lower urinary tract. Springer, New York, pp 3-22
16. Brading A (1987) Physiology of bladder smooth muscle. In: Torrens M, Morrison JFB (eds) The physiology of the lower urinary tract. Springer, New York, pp 161-192
17. Akbar M, Abel R, Seyler TM et al (2007) Repeated botulinum-A toxin injections in the treatment of myelodysplastic children and patients with spinal cord injuries with neurogenic bladder dysfunction. BJU Int 100:639-645 (Pubitemid 47205449)
18. Kuo HC (2004) Urodynamic evidence of effectiveness of botulinum A toxin injection in treatment of detrusor overactivity refractory to anticholinergic agents. Urology 63:868-872
19. Kuo HC (2005) Clinical effects of suburothelial injection of botulinum A toxin on patients with nonneurogenic detrusor overactivity refractory to anticholinergics. Urology 66:94-98
20. Schurch B, Denys P, Kozma CM et al (2007) Reliability and validity of the incontinence quality of Life questionnaire in patients with neurogenic urinary incontinence. Arch Phys Med Rehabil 88:646-652 (Pubitemid 46656251)
21. Hori S, Patki P, Attar KH (2009) Patients' perspective of botulinum toxin-A as a long-term treatment option for neurogenic detrusor overactivity secondary to spinal cord injury. BJU Int 104:216-220
22. Grosse J, Kramer G, Stohrer M (2005) Success of repeat detrusor injections of botulinum a toxin in patients with severe neurogenic detrusor overactivity and incontinence. Eur Urol 47:653-659 (Pubitemid 40521915)
23. Schulte-Baukloh H, Knispel HH, Stolze T et al (2005) Repeated botulinum-A toxin injections in treatment of children with neurogenic detrusor overactivity. Urology 66: 865-870 (Pubitemid 41440842)
24. Dressler D, Hallett M (2006) Immunological aspects of botox, dysport and myobloc/neurobloc. Eur J Neurol 13(Suppl. 1):11-15
25. Herrmann J, Geth K, Mall V et al (2004) Clinical impact of antibody formation to botulinum toxin A in children. Ann Neurol 55:732-735 (Pubitemid 38544335)